Ovandrotone albumin (INN , BAN ) (brand names Fecundin, Ovastim),[1] also known as polyandroalbumin, as well as ovandrotone:human serum albumin conjugate, is an immunogen and vaccine against androstenedione that is used in veterinary medicine to increase the ovulation rate and number of lambs born to ewes.[2][3][4][5] It is a conjugate of ovandrotone (androstenedione-7α-carboxyethylthioether)[6] and human serum albumin.[5] The drug was developed by 1981 and was introduced in Australia and New Zealand in 1983.[4][7]
Combination of | |
---|---|
Ovandrotone | Androstane steroid |
Human serum albumin | Serum protein |
Clinical data | |
Trade names | Fecundin, Ovastim |
Other names | Polyandroalbumin; GR-33207; Ovandrotone:human serum albumin conjugate |
AHFS/Drugs.com | Monograph |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number |
|
ChemSpider |
|
UNII |
|
Ovandrotone albumin produces transient immunity against androstenedione,[8] and the generation of antibodies against androstenedione presumably decreases circulating levels of androstenedione.[7] This is thought to result in reduced negative feedback on the hypothalamic-pituitary-gonadal axis and increased gonadotropin secretion, which in turn improves fertility and fecundity.[4] Indeed, ovandrotone albumin has been found to significantly increase luteinizing hormone levels throughout the estrous cycle in ewes.[4]